This medication is used in situations involving certain distressing symptoms across multiple therapeutic domains. It is commonly used in contexts where supportive symptom management is appropriate for managing symptoms associated with Parkinson's disease, conditions involving hyperprolactinemia, and the prophylaxis of severe headaches like migraine and cluster headache.

The drug is commonly used across conditions presenting with fluctuating symptom patterns or systemic imbalance. For individuals with movement disorders, it helps address symptom clusters that may become intense or disruptive, such as tremor, rigidity, and motor fluctuations. For endocrine purposes, it contributes to easing the overall symptom load by assisting with the management of symptoms linked to organ-specific functional stress. It may be part of symptomatic management associated with acute or episodic changes, including those of Restless Leg Syndrome (RLS).

“The medication is applied across domains where additional symptomatic support is needed, helping to manage symptoms that interfere with daily functioning.”

This supportive role in symptom management contributes to maintaining functional stability and helps patients cope more steadily with difficult episodes.

---

Quick Fact: May assist with Motor Fluctuations

Dopergin (Lisuride maleate) eligibility is determined by strict regulatory rules, particularly due to its class as an ergot derivative.

---

Absolute Contraindications

The medicine is contraindicated and must not be used by specific populations, including patients with a known hypersensitivity to Lisuride or other ergot derivatives. Absolute exclusion also applies to patients with severe, uncontrolled hypertension, coronary insufficiency, or severe peripheral arterial disorders. Furthermore, Dopergin is contraindicated in breastfeeding women because its primary action suppresses prolactin and thus lactation.

---

Restricted and Conditional Use

Use is not recommended in the pediatric population (children and adolescents) as safety and effectiveness have not been established. Pregnant women are generally advised against using Dopergin. Use requires caution in the geriatric population and in patients with compromised hepatic (liver) function due to the drug's metabolism. Patients must also be monitored for signs of fibrotic reactions if they take the medicine long-term.

Interactions with other medicines and products

The interaction profile of Dopergin (Lisuride maleate) is defined by its actions as a dopamine and serotonin receptor agonist, which establishes restrictions against co-administration with specific medicinal product classes.

Documented Interaction Patterns

Interaction Type	Interacting Substance/Class	Official Regulatory Statement
Pharmacodynamic Antagonism	Dopamine Antagonists (e.g., Antipsychotics)	Co-administration is formally restricted due to the potential for mutual antagonism and reduced efficacy.
Pharmacokinetic Modification	Potent CYP3A4 Inhibitors (e.g., certain antibiotics, antifungals)	Officially documented to increase the plasma concentration of Lisuride by reducing its metabolic clearance.
Pharmacokinetic Modification	Potent CYP3A4 Inducers	Documented to decrease the plasma concentration of Lisuride, potentially reducing its therapeutic exposure.
Pharmacodynamic Augmentation	CNS Depressants	Interaction results in additive central nervous system depressant effects.

Co-administration with Serotonergic Agents carries a documented risk of potentially increasing the serotonergic load. Furthermore, the use of Alcohol is restricted due to its ability to potentiate the sedative effects of CNS-active agents. Regulatory prescribing information defines these combinations as clinically significant or, in the case of strong antagonists, formally contraindicated, based on the established pharmacokinetic and pharmacodynamic profiles.

Dopergin, which is pergolide, functions primarily as an agonist at central nervous system D2 and D3 dopamine receptors. It also demonstrates activity at D1 dopamine receptors, and exhibits partial agonist or antagonist activity at alpha1- and alpha2-adrenergic and 5- HT (serotonin) receptors.

The principal mechanism involves the D2-like receptor subfamily ( D2, D3) found primarily on postsynaptic neurons within the nigrostriatal pathway, which is involved in motor function modulation. As a G-protein coupled receptor (GPCR) coupled to the inhibitory Gi protein, D2 receptor activation by pergolide inhibits the enzyme adenylyl cyclase. This inhibition results in a downstream decrease in the intracellular concentration of the second messenger cyclic adenosine monophosphate (cAMP). Simultaneously, receptor activation blocks the IP3-dependent release of Ca^2+ from intracellular stores and decreases calcium influx through voltage-gated channels. The D2 stimulation also inhibits the phosphorylation cascade involving p42/ p44 MAPK (Mitogen-Activated Protein Kinase). The resulting system-level physiological consequence of this direct postsynaptic stimulation is the modulation of coordinated muscle activity within the basal ganglia output pathways.

The administration of Dopergin (Lisuride maleate) is officially structured by its route, the necessary initial dose adjustments, and a specific discontinuation procedure. This medicine is formulated for oral ingestion as a tablet, which must be swallowed whole without crushing or chewing.

For gastrointestinal tolerability, particularly during the initiation phase, the medication is generally directed to be taken with meals or food. The core principle of usage across all approved indications involves individualized titration. Treatment begins at a low starting amount, and the dose is gradually increased over time according to official protocols until a stable maintenance dose is reached.

The total daily dosage is typically administered in divided doses taken multiple times per day. While use for chronic conditions is long-term, specific short-term courses, such as those for lactation suppression, have a defined duration, with daily doses typically ranging from 0.4 mg to 0.6 mg.

High-level administration rules exist for specific populations. For older adults, the process of dose increase must be executed more slowly than in younger patients. Furthermore, the protocol mandates that the medicine must not be stopped abruptly; instead, the dose must be progressively reduced (tapered) over a period of time to complete the full use protocol. This required step of gradual reduction is a necessary component of the official administration guidelines for the product.

Research evidence / Overview of studies for Dopergin (Lisuride Maleate)

Evidence for use in Parkinson's Disease (PD)

Research examined Dopergin (Lisuride) in the context of symptoms associated with Parkinson's disease (PD), a condition characterized by fluctuating or episodic manifestations. The evidence includes randomized controlled trials (RCTs) where the substance was evaluated in adults, including those with advanced PD. Studies monitored outcomes reflecting daily functioning using rating scales to measure changes in physical discomfort like tremor and rigidity. Research also examined whether the substance was associated with measurements of motor fluctuations. Comparative evidence is lacking against many other pharmacological agents studied for PD, and long-term effects are not fully established.

---

Evidence for use in Conditions Involving High Prolactin Levels (Hyperprolactinemia)

Dopergin was evaluated in studies observing responses over defined time intervals related to excess prolactin hormone, known as hyperprolactinemia. Clinical trials were evaluated in women experiencing associated symptoms and patients with pituitary tumors. The research examined outcomes related to systemic imbalance, primarily focusing on measurements of prolactin levels. Studies monitored changes in daily functioning, and patterns related to changes in tumor size were observed in some studies. Certainty remains low for long-term patterns once treatment has stopped, and evidence quality varies across studies when comparing it to all available pharmacological treatments.

---

Evidence for use in Preventing Severe Headaches

Research explored the use of Dopergin in research contexts involving fluctuating or unstable symptoms related to severe headaches, including migraine and cluster headache. Clinical trials were evaluated in adults. The studies monitored outcomes describing episodic or acute changes, primarily focusing on whether the number of headache attacks per month was evaluated in relation to the study substance. Researchers also examined patient-reported outcomes describing perceived discomfort and changes in the reliance on acute medication. Evidence is limited in volume, sample sizes were modest, and long-term effects are not fully established regarding the sustained management of outcomes related to attacks beyond the trials.

---

Long-Term Studies and Follow-up Data

Research was studied for varying periods, with follow-up durations were limited in many controlled trials. Long-term effects are not fully established across all indications. Although some studies explored observation periods of up to a few years, research primarily highlights changes measured during the study period but often provides limited information for long-term outcomes after treatment discontinuation.

---

Evidence in Specific or Limited-Data Populations

The results apply only to the populations studied, which were predominantly adults in trials. Data for certain groups remain insufficient; specifically, subgroup findings are uncertain for children, adolescents, or pregnant populations, as these groups were not broadly observed in the available research.

---

What is Still Uncertain About Dopergin Research

The overall research base contributes to the broader evidence landscape, but evidence quality varies across studies, with some key findings originating from older research. Certainty remains low regarding the long-term clinical patterns. Comparative evidence is lacking against many treatments, and subgroup findings are uncertain for many populations not explicitly included in the main trials.

Common questions about Dopergin (FAQ)

---

Q: What is Dopergin used for besides the main condition?

While Lisuride maleate (Dopergin) is mainly known for regulating prolactin levels and motor control, official research documentation indicates it has been investigated for other uses. This includes studies for conditions such as pulmonary arterial hypertension. It has also received an Orphan Designation status in some regulatory regions for conditions like Fragile X Syndrome, which supports research into its potential use for rare diseases.

Q: Can Dopergin cause feelings of anxiety or irritability?

Official product information describes potential effects on the nervous system. Evidence shows that anxiety has been associated with the use of Lisuride, particularly when higher amounts of the medication are administered. When feelings of anxiety or irritability occur, patients are typically advised to report this information to their healthcare provider.

Q: How long does Dopergin typically stay in the body's system?

The length of time Dopergin (Lisuride maleate) stays in the bloodstream is described by its elimination half-life, which is determined through pharmacokinetic studies. For the oral tablet, the mean plasma elimination half-life has been reported to be approximately 2 to 2.9 hours in adults. This figure describes the time it takes for half of the substance to be cleared from the plasma.

Q: Is Dopergin approved in European countries?

Yes, Lisuride has a long history of use and regulatory acceptance outside of the United States. Official historical documents indicate that the substance was approved for use in European countries for more than 20 years, as of 2004, for indications such as Parkinson’s disease.

Q: How long has Dopergin been on the market since its initial approval?

The active ingredient, Lisuride, was first synthesized in 1960. Historical regulatory sources confirm that the substance has been available in European markets for over two decades. The research base therefore includes data spanning a substantial period of time.

Q: Is there recent research or new trials looking at Dopergin?

Studies and official information indicate that ongoing or recent research is examining new applications and formulations for Lisuride. This includes investigations into the potential treatment of Fragile X Syndrome, for which it received an Orphan Drug Designation in 2022. Additionally, new pharmaceutical forms, such as patch formulations for Parkinson's disease, are being explored.

Q: Is Dopergin the same type of drug as bromocriptine or cabergoline?

Lisuride maleate (Dopergin) is categorized as a dopamine receptor agonist and an ergot derivative. Official chemical and pharmacological classifications indicate that it is similar in its class of action to other ergot-derived dopamine agonists, such as bromocriptine. This classification helps define its general mechanism and interaction profile.

Q: What does 'dopaminergic' mean in terms for a patient?

Dopergin is a dopamine receptor agonist, which means it acts directly upon the body's dopamine system, an action referred to as 'dopaminergic.' According to its mechanism, this action in the brain helps regulate processes like prolactin hormone levels and motor control.

Q: Does Dopergin have any known impact on liver function or tests?

Regulatory pharmacokinetic information indicates that Lisuride is metabolized, or broken down, extensively by the liver. Its degradation products are then eliminated from the body in roughly equal amounts via both the kidney and the liver. This process is the basis for regulatory statements regarding caution in patients with compromised liver function.

Q: What is the success rate described in the research evidence for Dopergin?

Research evidence focuses on measurements of patient outcomes rather than a single success rate percentage. Clinical trials have examined improvements in key symptom severity measures associated with the targeted conditions. For example, some studies showed a statistically and clinically significant improvement in the total score of the scale used to evaluate Parkinson's disease symptoms.

Q: Why is Dopergin sometimes restricted or given a black box warning by regulatory bodies?

The need for caution in prescribing Dopergin is related to its classification as an ergot derivative. While Lisuride has been distinguished by a reported absence of cardiac valvulopathy (heart valve damage) seen with some other drugs in its class, regulatory guidance emphasizes the need for close monitoring for serious but rare fibrotic side effects. This monitoring requirement reflects the caution associated with ergot-derived medicines.

How to Store and Dispose of Dopergin

All storage and disposal requirements for Dopergin (Lisuride maleate) oral tablets are strictly defined by regulatory labeling to maintain the product's stability.

Storage Requirements

The medication must be stored at a temperature below 25°C (77°F). Storage must ensure that the tablets are protected from light and moisture, meaning they must remain in the original container until use. It is explicitly stated that Dopergin should not be refrigerated or frozen.

Handling and Disposal

As a crucial safety measure, Dopergin must be stored out of the sight and reach of children. When the medication is expired or unused, disposal must comply with local regulations for pharmaceutical waste, such as a drug take-back program. Official instructions prohibit disposing of the product into wastewater or household trash, emphasizing the need for safe and environmentally compliant handling.